サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1342819

緑膿菌感染症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測

Global Pseudomonas Aeruginosa Infection Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 290 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
緑膿菌感染症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
出版日: 2023年08月01日
発行: Value Market Research
ページ情報: 英文 290 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

緑膿菌感染症治療市場の世界需要は、調査期間2023～2030年のCAGR 8.72%で、2022年の45億2,000万米ドルから2030年には88億2,000万米ドル近くの市場規模に達すると推定されます。

緑膿菌は、手術後に感染症を引き起こす可能性のある細菌の一種です。この細菌は血液、肺、その他の身体部位に感染する可能性があります。緑膿菌の治療には、多くの薬剤、治療法、個人の状態を軽減するための処置が含まれます。緑膿菌感染症の治療には、一般的に抗生物質やその他の薬剤が使用されます。

市場力学：

緑膿菌感染症治療市場は、世界中で消化管感染症、尿路感染症、呼吸器系感染症などの院内感染症の発生率と有病率が増加していることから、著しい成長を遂げる可能性が高いです。さらに、緑膿菌の流行とこの疾患に対する意識の高まりにより、市場は大幅に拡大すると推定されます。それにもかかわらず、拡大戦略を採用し、臨床試験中の新しい治療法の強固なパイプラインは、市場プレーヤーに十分な機会を提供する可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、緑膿菌感染症治療の世界市場における各セグメントを包括的に評価することもできます。緑膿菌感染症治療業界の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析：

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおける緑膿菌感染症治療市場の現在および将来の需要を強調する地域展望をカバーします。さらに、本レポートでは、著名な全地域における個々のアプリケーションセグメントの需要・推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 緑膿菌感染症治療- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 COVID-19発生の影響分析

第6章 緑膿菌感染症治療の世界市場分析：薬剤タイプ別

  • 薬剤タイプ別概要
  • 実績データと予測データ
  • 薬剤タイプ別分析
  • 単剤療法
  • 併用療法

第7章 緑膿菌感染症治療の世界市場分析：薬剤タイプ別

  • 薬剤タイプ別概要
  • 実績データと予測データ
  • 薬剤タイプ別分析
  • アミノグリコシド系
  • セファロスポリン
  • カルバペネム
  • モノバクタム
  • その他

第8章 緑膿菌感染症治療の世界市場分析：投与経路別

  • 投与経路別概要
  • 実績データと予測データ
  • 投与経路別分析
  • 経鼻
  • 経口
  • 静脈注射

第9章 緑膿菌感染症治療の世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 緑膿菌感染症治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第11章 緑膿菌感染症治療企業の競合情勢

  • 緑膿菌感染症治療市場の競合
  • パートナーシップ/提携/合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第12章 企業プロファイル

  • 上位企業シェア分析
  • 市場集中度
  • Allergan
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Lupin Pharmaceuticals Inc.
  • AstraZeneca
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Co.
  • Janssen Pharmaceuticals Inc.
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Medication Type (USD MN)
  • Monotherapy Market Sales by Geography (USD MN)
  • Combination Therapy Market Sales by Geography (USD MN)
  • Analysis Market by Drug Type (USD MN)
  • Aminoglycoside Market Sales by Geography (USD MN)
  • Cephalosporin Market Sales by Geography (USD MN)
  • Carbapenem Market Sales by Geography (USD MN)
  • Monobactam Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Route Of Administration (USD MN)
  • Nasal Market Sales by Geography (USD MN)
  • Oral Market Sales by Geography (USD MN)
  • Intravenous Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Pseudomonas Aeruginosa Infection Treatment Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Pseudomonas Aeruginosa Infection Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Pseudomonas Aeruginosa Infection Treatment Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Medication Type
  • Market Attractiveness Analysis by Drug Type
  • Market Attractiveness Analysis by Route Of Administration
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Medication Type (USD MN)
  • Monotherapy Market Sales by Geography (USD MN)
  • Combination Therapy Market Sales by Geography (USD MN)
  • Global Market Analysis by Drug Type (USD MN)
  • Aminoglycoside Market Sales by Geography (USD MN)
  • Cephalosporin Market Sales by Geography (USD MN)
  • Carbapenem Market Sales by Geography (USD MN)
  • Monobactam Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Route Of Administration (USD MN)
  • Nasal Market Sales by Geography (USD MN)
  • Oral Market Sales by Geography (USD MN)
  • Intravenous Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11219629

The global demand for Pseudomonas Aeruginosa Infection Treatment Market is presumed to reach the market size of nearly USD 8.82 BN by 2030 from USD 4.52 BN in 2022 with a CAGR of 8.72% under the study period 2023 - 2030.

Pseudomonas aeruginosa is a class of bacteria that can cause infections in individuals after a surgery. This can infect blood, lungs, or any other body part. Pseudomonas aeruginosa treatment may involve a number of drugs, therapies, and procedures that help lessen an individual's condition. Antibiotics and other medications are typically used to treat Pseudomonas aeruginosa infections.

MARKET DYNAMICS:

The pseudomonas aeruginosa infection treatment market is likely to experience remarkable growth owing to the increasing incidence and prevalence of hospital-acquired infections such as gastrointestinal infections, urinary tract infections, and respiratory system infections across the globe. Additionally, the market is estimated to increase significantly owing to the prevalence of pseudomonas aeruginosa and the surge in awareness about the disease. Nonetheless, adopting expansion strategies and a robust pipeline of new therapies in clinical trials could provide ample opportunities for market players.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pseudomonas aeruginosa infection treatment. The growth and trends of pseudomonas aeruginosa infection treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pseudomonas aeruginosa infection treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Medication Type

  • Monotherapy
  • Combination Therapy

By Drug Type

  • Aminoglycoside
  • Cephalosporin
  • Carbapenem
  • Monobactam
  • Others

By Route Of Administration

  • Nasal
  • Oral
  • Intravenous

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Pseudomonas Aeruginosa Infection Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pseudomonas aeruginosa infection treatment market include Allergan, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Lupin Pharmaceuticals Inc., AstraZeneca, Merck & Co. Inc., Bristol-Myers Squibb Co., Janssen Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . PSEUDOMONAS AERUGINOSA INFECTION TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Medication Type
    • 3.7.2 Market Attractiveness Analysis By Drug Type
    • 3.7.3 Market Attractiveness Analysis By Route Of Administration
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET ANALYSIS BY MEDICATION TYPE

  • 6.1 Overview by Medication Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Medication Type
  • 6.4 Monotherapy Historic and Forecast Sales by Regions
  • 6.5 Combination Therapy Historic and Forecast Sales by Regions

7 . GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET ANALYSIS BY DRUG TYPE

  • 7.1 Overview by Drug Type
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Drug Type
  • 7.4 Aminoglycoside Historic and Forecast Sales by Regions
  • 7.5 Cephalosporin Historic and Forecast Sales by Regions
  • 7.6 Carbapenem Historic and Forecast Sales by Regions
  • 7.7 Monobactam Historic and Forecast Sales by Regions
  • 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 8.1 Overview by Route Of Administration
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Route Of Administration
  • 8.4 Nasal Historic and Forecast Sales by Regions
  • 8.5 Oral Historic and Forecast Sales by Regions
  • 8.6 Intravenous Historic and Forecast Sales by Regions

9 . GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 9.1 Overview by Distribution Channel
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Distribution Channel
  • 9.4 Hospital Pharmacies Historic and Forecast Sales by Regions
  • 9.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 9.6 Online Pharmacies Historic and Forecast Sales by Regions

10 . GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1. Overview, Historic and Forecast Sales Analysis
    • 10.3.2. North America By Segment Sales Analysis
    • 10.3.3. North America By Country Sales Analysis
    • 10.3.4. United State Sales Analysis
    • 10.3.5. Canada Sales Analysis
    • 10.3.6. Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1. Overview, Historic and Forecast Sales Analysis
    • 10.4.2. Europe by Segment Sales Analysis
    • 10.4.3. Europe by Country Sales Analysis
    • 10.4.4. United Kingdom Sales Analysis
    • 10.4.5. France Sales Analysis
    • 10.4.6. Germany Sales Analysis
    • 10.4.7. Italy Sales Analysis
    • 10.4.8. Russia Sales Analysis
    • 10.4.9. Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1. Overview, Historic and Forecast Sales Analysis
    • 10.5.2. Asia Pacific by Segment Sales Analysis
    • 10.5.3. Asia Pacific by Country Sales Analysis
    • 10.5.4. China Sales Analysis
    • 10.5.5. India Sales Analysis
    • 10.5.6. Japan Sales Analysis
    • 10.5.7. South Korea Sales Analysis
    • 10.5.8. Australia Sales Analysis
    • 10.5.9. Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1. Overview, Historic and Forecast Sales Analysis
    • 10.6.2. Latin America by Segment Sales Analysis
    • 10.6.3. Latin America by Country Sales Analysis
    • 10.6.4. Brazil Sales Analysis
    • 10.6.5. Argentina Sales Analysis
    • 10.6.6. Peru Sales Analysis
    • 10.6.7. Chile Sales Analysis
    • 10.6.8. Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1. Overview, Historic and Forecast Sales Analysis
    • 10.7.2. Middle East & Africa by Segment Sales Analysis
    • 10.7.3. Middle East & Africa by Country Sales Analysis
    • 10.7.4. Saudi Arabia Sales Analysis
    • 10.7.5. UAE Sales Analysis
    • 10.7.6. Israel Sales Analysis
    • 10.7.7. South Africa Sales Analysis
    • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT COMPANIES

  • 11.1. Pseudomonas Aeruginosa Infection Treatment Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12 . COMPANY PROFILES OF PSEUDOMONAS AERUGINOSA INFECTION TREATMENT INDUSTRY

  • 12.1. Top Company Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Allergan
    • 12.3.1. Company Overview
    • 12.3.2. Company Revenue
    • 12.3.3. Products
    • 12.3.4. Recent Developments
  • 12.4. Teva Pharmaceutical Industries Ltd.
    • 12.4.1. Company Overview
    • 12.4.2. Company Revenue
    • 12.4.3. Products
    • 12.4.4. Recent Developments
  • 12.5. Pfizer Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Company Revenue
    • 12.5.3. Products
    • 12.5.4. Recent Developments
  • 12.6. Lupin Pharmaceuticals Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Company Revenue
    • 12.6.3. Products
    • 12.6.4. Recent Developments
  • 12.7. AstraZeneca
    • 12.7.1. Company Overview
    • 12.7.2. Company Revenue
    • 12.7.3. Products
    • 12.7.4. Recent Developments
  • 12.8. Merck & Co. Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Company Revenue
    • 12.8.3. Products
    • 12.8.4. Recent Developments
  • 12.9. Bristol-Myers Squibb Co.
    • 12.9.1. Company Overview
    • 12.9.2. Company Revenue
    • 12.9.3. Products
    • 12.9.4. Recent Developments
  • 12.10. Janssen Pharmaceuticals Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Company Revenue
    • 12.10.3. Products
    • 12.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies